The lab will use its phlebotomy network to help Grail with specimen collection for its Galleri multi-cancer early detection blood test, slated to launch this year.
The work is part of a CDC project to identify novel mutations in the virus and better understand its prevalence and patterns of transmission throughout the US.
Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.
While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.
Williams v Quest/Athena struck a nerve with the genetic testing community by probing what the standard of care is and ought to be for variant classification.
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
